

Blue Cross and Blue Shield of Vermont and The Vermont Health Plan Prior Approval Guidelines Letairis™ (ambrisentan)

DESCRIPTION: This is an endothelin receptor antagonist that is selective for the endothelin type-A (ET_A) receptor. This agent has a high affinity for endothelin type-A receptor agonist.

INDICATION(S): Treatment of pulmonary arterial hypertension (WHO group 1) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening.

REASONS FOR Step Therapy: Cost Potential for misuse Toxicity

CRITERIA for APPROVAL: Patient has a diagnosis of Pulmonary Artery Hypertension with WHO class II or III symptoms

REASON for DENIAL of BENEFIT: Patient has a hypersensitivity to Letairis or any of its components
Patient does not meet above criteria.
Patient is pregnant or may become pregnant
Patient has moderate or severe hepatic impairment
Patient is concurrently taking Cyclosporin A
Patient is less than eighteen years of age

BENEFIT APPROVAL: Approval for a one year

References: Package Insert Letairis™, Gilead Sciences, Inc. Foster City, CA 94404